Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 19/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 11/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 11/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4162558 | 0.95 | CHRM3 (0.90) | CHRM3CHRM2CHRM1 | |
| SCHEMBL5432731 | 0.95 | CHRM3 (0.90) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4162557 | 0.95 | CHRM3 (0.90) | CHRM3CHRM2CHRM1 | |
| SCHEMBL3911914 | 0.88 | CHRM3 (0.79) | CHRM3CHRM2CHRM1 | |
| SCHEMBL3913838 | 0.88 | CHRM3 (0.79) | CHRM3CHRM2CHRM1 | |
| SCHEMBL3911912 | 0.88 | CHRM3 (0.79) | CHRM3CHRM2CHRM1 | |
| SCHEMBL13717380 | 0.86 | CHRM3 (0.75) | CHRM3CHRM2CHRM1 | |
| SCHEMBL13749342 | 0.84 | CHRM3 (0.73) | CHRM3CHRM2CHRM1 | |
| SCHEMBL13717262 | 0.83 | CHRM3 (0.71) | CHRM3CHRM2CHRM1 | |
| SCHEMBL141495 | 0.80 | CHRM3 (0.67) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1677795-B1 | MUSCARINIC ACETYCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2011-01-05 | — | — | EP | disclosed |
| US-7579361-B2 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-25 | — | — | US | disclosed |
| US-7579361-B2 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-25 | — | — | US | disclosed |
| US-7579361-B2 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-25 | — | — | US | disclosed |
| US-7576096-B2 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-18 | — | — | US | disclosed |
| US-7576096-B2 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-18 | — | — | US | disclosed |
| US-7576096-B2 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-18 | — | — | US | disclosed |
| US-20070244150-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED | 2007-10-18 | — | — | US | disclosed |
| US-20070244150-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED | 2007-10-18 | — | — | US | disclosed |
| US-20070244150-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED | 2007-10-18 | — | — | US | disclosed |
| US-20070238752-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED | 2007-10-11 | — | — | US | disclosed |
| US-20070238752-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED | 2007-10-11 | — | — | US | disclosed |
| US-20070238752-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED | 2007-10-11 | — | — | US | disclosed |
| US-7276521-B2 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-7276521-B2 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-20070105895-A1 | Muscarinic acetycholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| US-20070105895-A1 | Muscarinic acetycholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| EP-1677795-A4 | MUSCARINIC ACETYCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2006-12-27 | — | — | EP | disclosed |
| EP-1677795-A1 | MUSCARINIC ACETYCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005037280-A1 | MUSCARINIC ACETYCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238752-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 19/4885 |
| US-20070244150-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 19/4885 |
| US-20070105895-A1 | Muscarinic acetycholine receptor antagonists | CHRM3, CHRNA7, CHRNA2 | CHRM3 1/4885CHRM2 7/4885CHRM1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.